The DoD Instruction 6130.03, Volume 2, outlines the retention standards for the U.S. Military, providing guidance on medical conditions and treatments that are disqualifying for all branches of the military. This document states that patients with conditions requiring immunomodulating or immunosuppressant medications do not meet retention standards. Eosinophilic esophagitis is a common, chronic inflammatory disease of the esophagus that typically presents with dysphagia. Although proton pump inhibitors are effective at treating this disease in some cases, swallowed topical steroids are the most frequently used therapy within the DoD. These medications act locally in the esophagus and do not cause systemic side effects typical of oral steroid therapy, including immunosuppression. They are effective at inducing and maintaining disease remission and are generally well tolerated, with minimal side effects. We propose a brief amendment to this document to clarify the language used and avoid inappropriate Medical Evaluation Board referrals.

中文翻译：

---

国防部保留标准中对嗜酸性食管炎治疗的澄清

国防部指令 6130.03 第 2 卷概述了美国军方的保留标准，为所有军队部门取消资格的医疗条件和治疗提供了指导。该文件指出，患有需要免疫调节或免疫抑制剂药物的患者不符合保留标准。嗜酸性粒细胞性食管炎是一种常见的慢性食管炎性疾病，通常表现为吞咽困难。尽管在某些情况下质子泵抑制剂可有效治疗这种疾病，但口服类固醇是国防部内最常用的治疗方法。这些药物在食道局部起作用，不会引起口服类固醇治疗典型的全身副作用，包括免疫抑制。它们可有效诱导和维持疾病缓解，并且通常耐受性良好，副作用最小。我们建议对本文件进行简短修订，以澄清所使用的语言并避免不适当的医学评估委员会转介。